1-6 of 6
R. Clark Clark Brown
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Etavopivat, an Allosteric Activator of Pyruvate Kinase-R, Improves Sickle RBC Functional Health and Survival and Reduces Systemic Markers of Inflammation and Hypercoagulability in Patients with Sickle Cell Disease: An Analysis of Exploratory Studies in a Phase 1 Study

Theodosia A. Kalfa, Marilyn J. Telen, Santosh L. Saraf, R. Clark Clark Brown, Katie Giger Seu, Sandra K. Larkin, Maria D. Ribadeneira, Patricia Schroeder, Eric Wu, Patrick Kelly, Frans A. Kuypers
Journal: Blood
Blood (2021) 138 (Supplement 1): 8.
https://doi.org/10.1182/blood-2021-147078
Published: 2021
Journal Articles

Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial

Maureen Achebe, Hoda Hassab, Salam Alkindi, R. Clark Clark Brown, Paul Telfer, Bart J. Biemond, Victor R. Gordeuk, Thokozeni Lipato, Margaret Tonda, Sarah Gray, Joanna Howard
Journal: Blood
Blood (2021) 138 (Supplement 1): 3114.
https://doi.org/10.1182/blood-2021-153582
Published: 2021
Journal Articles

GBT021601, a Next Generation HbS Polymerization Inhibitor: Results of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Adults Living with Sickle Cell Disease and Healthy Volunteers

R. Clark Clark Brown, Andrew Redfern, Eleanor Lisbon, Carla Washington, Irene Agodoa, Kim Smith-Whitley
Journal: Blood
Blood (2021) 138 (Supplement 1): 3099.
https://doi.org/10.1182/blood-2021-152924
Published: 2021
Journal Articles

Trial in Progress: A Phase 2, Open-Label Study Evaluating the Safety and Efficacy of the PKR Activator Etavopivat (FT-4202) in Patients with Thalassemia or Sickle Cell Disease

Ashutosh Lal, R. Clark Clark Brown, Thomas D. Coates, Theodosia A. Kalfa, Janet L. Kwiatkowski, Julie Brevard, Von Potter, Ken W. Wood, Sujit Sheth
Journal: Blood
Blood (2021) 138 (Supplement 1): 4162.
https://doi.org/10.1182/blood-2021-145752
Published: 2021
Journal Articles

Activation of Pyruvate Kinase-R with Etavopivat (FT-4202) Is Well Tolerated, Improves Anemia, and Decreases Intravascular Hemolysis in Patients with Sickle Cell Disease Treated for up to 12 Weeks

R. Clark Clark Brown, Santosh L. Saraf, Kimberly Cruz, Modupe Idowu, Theodosia A. Kalfa, James Geib, Sanjeev Forsyth, Patricia Schroeder, Eric Wu, Patrick Kelly, Marilyn J. Telen
Journal: Blood
Blood (2021) 138 (Supplement 1): 9.
https://doi.org/10.1182/blood-2021-147091
Published: 2021
Journal Articles

Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD)

Matthew M. Heeney, David C. Rees, Mariane De Montalembert, Isaac Odame, R. Clark Clark Brown, Yasser Wali, Thu Thuy Nguyen, Du Lam, Nadege Pfender, Julie Kanter
Journal: Blood
Blood (2021) 138 (Supplement 1): 12.
https://doi.org/10.1182/blood-2021-144730
Published: 2021